Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Safety monitoring and information (126)
- Compliance and enforcement (33)
- Import and export (30)
- Shortages and supply disruptions (16)
- Sunscreens (9)
- Advertising (6)
- COVID-19 (5)
- Labelling and packaging (4)
- Weight loss products (4)
- Breast implant hub (3)
- Manufacturing (3)
- Legislation (2)
- Cosmetics (1)
- Metal-on-metal hip replacement implants hub (1)
Type of content
Search
783 result(s) found, displaying 601 to 625
-
Safety alerts
-
Safety alerts
-
Market actions
-
Safety alertsYong Gang tablets contain undeclared prescription substances and pose serious health risks. Stop using them and return any remaining tablets to your pharmacy. Consult your doctor if you have concerns.
-
Safety alerts
-
-
Safety alertsThe TGA has issued updated safety advice for health professionals regarding dabigatran (Pradaxa), highlighting the increased risk of bleeding and the importance of careful patient selection and monitoring, especially in older adults and those with kidney impairment.
-
Safety alertsTGA has issued updated safety advice for consumers taking Pradaxa (dabigatran), highlighting risks such as bleeding and the importance of proper storage and patient monitoring.
-
-
Safety alerts
-
Safety alerts
-
Safety alerts
-
Safety alerts
-
Safety alerts
-
Safety alerts
-
Safety alerts
-
Safety alerts
-
Safety alertsPrecautionary product notification for GlaxoSmithKline Australia (GSK) influenza vaccine, Fluarix
-
-
Safety alerts
-
Safety alertsAbout seasonal flu vaccine: 2013 seasonal influenza vaccines for use in children
-
Safety alerts
-
-
Safety alertsThe TGA has performed and reported on a large number of tests on the chemical properties, physical properties and the biological safety of the gels and shells of PIP breast implants.
-